Most Read Articles
Roshini Claire Anthony, 05 Apr 2021

Primary analysis of the D8110C00001 trial showed that the COVID-19 vaccine AZD1222 had 76 percent efficacy at preventing symptomatic COVID-19.

Roshini Claire Anthony, 12 Apr 2021

Treatment with the human monoclonal antibody tezepelumab reduced exacerbations and improved asthma control, lung function, and quality of life in adults and adolescents with severe, uncontrolled asthma, according to the phase III NAVIGATOR study presented as a poster at AAAAI 2021.

Audrey Abella, 16 Mar 2021
Following the administration of the first dose of the Pfizer-BioNTech COVID-19 vaccine between December 14 and 23, 2020 in the US, 21 cases of anaphylaxis have been recorded, equating to an initial estimated rate of 11.1 cases/million doses administered, according to a joint report from the US FDA and the CDC* COVID-19 Response Team.
Pearl Toh, 28 Apr 2021
Impaired smell function occurs more commonly in people with mild rather than moderate-to-critical forms of COVID-19 illness, a study finds.

Seizure ups risk of respiratory failure, death in children with pneumonia

6 days ago

Risk factors for seizure in children with pneumonia must be identified early for clinicians to treat them straightaway and potentially reduce deaths in these patients, particularly in resource-limited settings, suggests a recent study.

A retrospective chart analysis was conducted on children under 5 years of age with World Health Organization classified clinical (excluding seizure as one of the clinical diagnostics) and radiologic pneumonia, admitted to the intensive care unit at Dhaka Hospital of icddr,b in Bangladesh between August 2013 and December 2019.

The investigators initially identified the children with pneumonia who had seizure. For comparison, they randomly selected controls from the rest of the children with pneumonia who had no seizure. Prevalence and outcome of seizure patients were then measured. Finally, factors related to seizure in children with pneumonia compared with those without seizure were identified.

Seizure was characterized by sudden, violent, involuntary, and abnormal repetitive movements with or without loss or impairment of consciousness confirmed by an attending physician.

A total of 4,101 children with pneumonia were identified, of whom 514 (12.5 percent) had seizure. Compared with those without seizure, children having both pneumonia and seizure were more likely to develop respiratory failure (18 percent vs 3 percent; p<0.001) and die (13 percent vs 3 percent; p<0.001) during hospitalization.

Logistic regression analysis revealed that hypoxaemia (95 percent confidence interval [CI], 1.59–3.17; p<0.001), severe pneumonia (95 percent CI, 2.13–6.52; p<0.001), severe sepsis (95 percent CI, 1.30–2.88; p=0.001), and hypernatraemia (95 percent CI, 5.31–10.93; p<0.001) were independently associated with a higher risk of seizure.

In contrast, children with pneumonia having seizure were less likely to develop severe acute malnutrition (95 percent CI, 0.26–0.50; p<0.001).

“Pneumonia is the leading infectious cause of deaths in children under 5 for the last few decades,” the investigators said. “Development of seizure in those children is common and associated with increased risk of deaths.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 05 Apr 2021

Primary analysis of the D8110C00001 trial showed that the COVID-19 vaccine AZD1222 had 76 percent efficacy at preventing symptomatic COVID-19.

Roshini Claire Anthony, 12 Apr 2021

Treatment with the human monoclonal antibody tezepelumab reduced exacerbations and improved asthma control, lung function, and quality of life in adults and adolescents with severe, uncontrolled asthma, according to the phase III NAVIGATOR study presented as a poster at AAAAI 2021.

Audrey Abella, 16 Mar 2021
Following the administration of the first dose of the Pfizer-BioNTech COVID-19 vaccine between December 14 and 23, 2020 in the US, 21 cases of anaphylaxis have been recorded, equating to an initial estimated rate of 11.1 cases/million doses administered, according to a joint report from the US FDA and the CDC* COVID-19 Response Team.
Pearl Toh, 28 Apr 2021
Impaired smell function occurs more commonly in people with mild rather than moderate-to-critical forms of COVID-19 illness, a study finds.